Related Experiment Video

Updated: Oct 11, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
00:06

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever

C Cazeneuve1, H Ajrapetyan, S Papin

  • 1Service de Biochimie et de Génétique Moléculaire and Institut National de la Santé et de la Recherche Médicale (Unité 468), H opital Henri-Mondor, 94010 Créteil, France.

American Journal of Human Genetics
|October 6, 2000
PubMed

Insights

Familial Mediterranean Fever (FMF) risk for renal amyloidosis is influenced by SAA1 genotype and patient sex, independent of MEFV mutations. These factors increase susceptibility to this severe complication.

Area of Science:

  • Genetics
  • Immunology
  • Nephrology

Background:

  • Familial Mediterranean Fever (FMF) is an inherited autoinflammatory disorder.
  • FMF predisposes patients to renal amyloidosis, a severe complication.
  • The MEFV gene mutations explain FMF but not all clinical variations, suggesting other factors are involved.

Purpose of the Study:

  • To identify genetic and non-genetic factors modifying renal amyloidosis risk in FMF patients.
  • To investigate the role of SAA1, SAA2, and APOE genes and sex as potential modifiers.

Main Methods:

  • Study population: 137 Armenian FMF patients from 127 families.
  • Statistical analysis: Stepwise logistic regression.
  • Candidate genes: SAA1, SAA2, APOE, and patient sex.

Main Results:

  • The SAA1alpha/alpha genotype significantly increased renal amyloidosis risk (OR=6.9).
  • Male patients had a fourfold higher risk of developing renal amyloidosis (OR=4.0).
  • SAA1 and sex acted independently of MEFV genotype and each other.

Conclusions:

  • Renal amyloidosis susceptibility in FMF is influenced by MEFV-independent factors.
  • SAA1 genotype and male sex are significant risk factors for renal amyloidosis in FMF.
  • These findings offer new insights into FMF pathophysiology and amyloidosis development.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Animal Mitochondrial Genetics02:59

Animal Mitochondrial Genetics

Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...